INTRODUCTION
Advances in manufacturing technology -including genetic manipulation -coupled with an improved understanding of the nature of pathogenic organisms, have allowed researchers to develop a wide range of safer, more effective veterinary biologicals. Free movement of veterinary biologicals across national borders is often greatly inhibited, however, due to concern over the potential for these products to introduce exotic diseases (C.G. Osborne, unpublished findings, 1992).
For the purpose of this paper, veterinary biologicals are categorised as follows:
-immunobiologicals (e.g. diagnostics, therapeutics, vaccines) -therapeutics (e.g. antitoxin, porcine somatotropin, bovine somatotropin) -raw materials and starting materials.
The Agreement on Sanitary and Phytosanitary Measures concluded at the Uruguay Round of the General Agreement on Tariffs and Trade (GATT; now World Trade Organisation: WTO) has led to globalisation of the veterinary manufacturing industry and an anticipated relaxation of trade restrictions. As a result, there is increasing pressure on regulatory authorities to develop and implement rational, scientificallybased protocols and strategies for determining the potential risks associated with veterinary biologicals and the raw materials from which these are made.
In Australia, a favourable animal disease status and strongly export-oriented animal industries have led to a relatively conservative view of import risk, which in turn has created a strong local industry for the manufacture of biologicals, with less reliance on imported products or components than might otherwise have been the case. In a country which relies on meat exports, exotic disease could have serious consequences for animal health, food supply and the economy (1) .
RISK ANALYSIS
Risk can be defined as the potential for the occurrence of negative consequences of an event. The use of risk analysis methodology should facilitate consistent and orderly decision-making. Risk analysis includes risk assessment, risk management, risk communication and monitoring. In the case of veterinary biologicals, the main purpose of risk analysis is to evaluate the likelihood that a viable exotic infectious organism could enter a country via a contaminated product. Another concern, however, is the possibility of spread of a non-exotic disease agent by the same route. This concern applies equally to antigen produced domestically and to antigen produced overseas. The potential for reversion to virulence of live vaccine agents is likewise a concern, whether the antigen is produced overseas or locally. There are also public health and environmental concerns. Both scientific judgements and policy choices are involved at certain decision points.
Risk assessment seeks to identify and characterise risks. Risk management, however, seeks to determine what action should be implemented to ensure that the risk is minimised or eliminated. Risk management incorporates not only risk communication, but also information on technical feasibility, cost and social benefits, as well as political factors.
RISK ASSESSMENT PROCESS IN AUSTRALIA
In Australia, different elements of risk assessment are the responsibility of different agencies, as described below.
Quarantine assessment
The Australian Quarantine and Inspection Service (AQIS) undertakes assessment of all biologicals entering Australia.
Assessment of efficacy, safety and standards compliance
The National Registration Authority for Agricultural and Veterinary Chemicals (NRA) undertakes assessment of all biological products for therapeutic use requiring registration in Australia.
Assessment of genetic safety
The Genetic Manipulation Advisory Committee (GMAC) assesses all biologicals which are produced by a process involving genetic manipulation.
The above agencies employ a screening risk assessment (SRA) method to evaluate the potential risks associated with veterinary biologicals. SRA uses simple worst-case scenarios and conservative data to set priorities and identify risks.
AUSTRALIAN POLICY ON IMPORTATION OF BIOLOGICAL PRODUCTS
It has long been recognised that judicious use of veterinary immunobiologicals can have enormous benefits in the economic, social and animal health spheres. However, these products may have the potential to spread harmful diseases if regulatory controls are not sufficient to assure efficacy, and to eliminate contamination by extraneous pathogens.
In view of the geographical position of Australia as an isolated continent, and the fact that the country is free from most major animal diseases (foot and mouth disease, rinderpest, rabies, hog cholera, velogenic Newcastle disease and all prion diseases of animals), in the past Australia has adopted a conservative approach to the importation of veterinary immunobiologicals.
Consequently, emphasis has been placed on obtaining biological reagents from domestic sources. When importation has been necessary to address new or emerging disease syndromes, introduction of seed organisms has been preferred to fullyformulated products. Importation of fully-formulated vaccines has been limited to inactivated products, and then only for special purposes or under restricted usage, e.g. for vaccination of livestock and companion animals to satisfy overseas requirements (1).
In the past, emphasis has been placed on the evaluation of veterinary immunobiologicals. Raw materials and starting materials present similar risks, however, and authorities are beginning to recognise the need to look beyond vaccines in order to maintain freedom from extraneous agents (1).
RISK ANALYSIS FOR IMPORTED VETERINARY BIOLOGICALS
The thrust of the current controls for the importation of veterinary biologicals is aimed at minimising the quarantine controls on lower-risk products while improving the controls and quarantine confidence on higher-risk material. To this end, AQIS has developed guidelines which detail quarantine concerns, assessment procedures and import requirements for biologicals. Prior to these guidelines, import permits were required for virtually all biologicals (2).
AQIS risk assessment for the importation and use of imported veterinary biologicals involves the following:
Risk identification
The data required to identify and characterise disease risk include the following: a) information on the molecular and biological properties of the product; b) potential for products to be derived from infected animals, and confidence in information received on the following matters: h) for genetically-modified products, evidence that the work would comply with the appropriate GMAC guidelines.
Low-risk materials
Low-risk veterinary biological products are those for which assessment using the above criteria indicates little likelihood of a viable exotic infectious organism being introduced via a contaminated product or component. Most low-risk products for in vitro diagnostic use are currently approved as 'items within biologicals catalogues' and may be imported without an import permit, provided that they are declared on quarantine entry, are accurately and adequately described, and meet specified conditions (2) .
High-risk materials
High-risk materials are imported biological materials which, when assessed using the above criteria, indicate the potential to present a greater quarantine risk. Importation of high-risk products requires a separate permit, and each case is treated on its merit. Examples of high-risk materials include the following (2):
-products for in vivo use, including starting materials -live microorganisms, or cell-lines -material restricted or subject to assessment by GMAC (e.g. geneticallymanipulated organisms [GMOs], vectors) -serum, serum proteins, and enzymes such as trypsin and pepsin -monoclonal and polyclonal antibodies.
Diagnostics
Diagnostics are typically in vitro products and are unlikely to be intentionally exposed to animals. There is a risk of accidental exposure, however, especially when the kit is being used in close proximity to animals. Many of these products contain antiserum, antibodies and other products of animal origin, usually from rodents, rabbits or (to a lesser extent) sheep, goats and bovines. They may also contain antigen from a pathogen of quarantine significance. The information considered by the risk assessment includes the following (2): -description of the product, proposed use and method of disposal -detailed list of all ingredients including volumes/amounts -detailed list of other biological products used and source(s) -species of animal(s) used and their country of origin -manufacturing process and steps taken to ensure that the product does not contain any viable pathogenic microorganisms of concern, including viruses -disease testing of the animals or plants of origin before and after slaughter or harvesting, and chemical and physical treatments during processing, extraction, preparation or purification -details of quality control procedures and innocuity testing either in vitro or in vivo.
Risk management
The importation of many biological products represents a potentially high quarantine risk. However, these products may be essential for research, therapeutics, environmental and analytical use, etc. To allow the importation of these biological products, assurances are required either that the products are safe for unrestricted use and distribution, or that adequate controls exist to ensure products are handled safely, are not exposed (either directly or indirectly) to animals, and are disposed of safely (2). This is achieved in Australia through the registration of institutions which use imported high-risk biologicals. To be registered, institutions must meet AQIS minimum requirements in laboratory handling procedures, waste management, containment facilities and personnel; in addition, the establishment must be committed to safe, proper handling and disposal of such material (2) . Registered institutions are required to establish a local biosafety committee, and to maintain an up-to-date inventory of imported biologicals used (2).
Risk monitoring
AQIS audits commercial importers to ensure compliance with the conditions of their import permit. This includes the condition that supply of restricted biologicals be limited to institutions registered with AQIS. Failure of an importer to comply with the conditions of the import permit attracts a heavy penalty under the Quarantine Act (1908). Institutions which are registered with AQIS are also audited to ensure compliance with requirements for handling, disposal and facilities, and to ensure that their register of imported biologicals is maintained.
RISK ANALYSIS FOR PRODUCTS OF MOLECULAR BIOLOGY
The risk analysis of products of genetic manipulation work is undertaken by GMAC. The scope of GMAC review includes the construction, propagation and/or deliberate release into the environment of viroids, viruses, cells or whole organisms of novel genotype, which are unlikely to occur in nature, or which may pose a hazard to public health or the environment. GMAC recommends appropriate safety procedures and the level of containment for the proposed study (7, 9) .
Any institution which conducts genetic manipulation work or imports GMOs is required to set up an Institutional Biosafety Committee (IBC). The local IBC reviews all proposals, supervises research activities, and monitors the day-to-day work within the establishment to ensure compliance with GMAC advice and guidelines (7, 9) .
Risk analysis
The nature of the risk assessment process for genetic manipulation studies depends on the type of work to be undertaken. GMAC publishes three sets of guidelines for genetic manipulation work, as follows:
-Guidelines for small scale genetic manipulation work (for work in a contained facility involving less than ten litres of cell culture) (6) -Guidelines for large scale work with genetically-manipulated organisms (for work in a contained facility involving more than ten litres of cell culture, or industrial scale work) (5) -Guidelines for the planned release of genetically-manipulated organisms (for work involving planned release of a GMO into the environment) (8).
The primary aim of the risk assessment process is to identify and characterise all possible hazards to workers, public health, the environment and agricultural production. To assess the hazards, the following information is required (4): -molecular and biological properties of the donor organism, the vector and the host cell -origin and identification of the gene being cloned -construction, genetics and structure of the expression vector -method by which the vector is introduced into the host cell -description of the nucleotide sequence of the gene -stability of the host vector expression system under conditions of storage and recovery -method of production and quality control -precise physico-chemical nature of the impurities -detailed information on the nature of the environment into which the GMO will be released.
When the risks inherent in the proposed work have been identified and characterised, the assessment determines whether or not safety hazards exist and, if so, what level of containment facility is required. To date, the host/vector systems used for genetic manipulation work in Australia have been in the lowest category of hazard.
Risk management for products of molecular biology

Small-scale work
Small-scale work is divided into categories A and B. Category A includes work which presents a risk to researchers, the community or the environment, or where there is uncertainty about the outcome. Category A work cannot begin without assessment and approval by GMAC. Category B work is defined as potentially presenting a lesser hazard; while notification to GMAC is required, the proposed work may begin after IBC assessment. Certain types of genetic manipulation work are exempt from GMAC guidelines (6) .
There are three containment levels (Cl, C2, and C3) for small-scale genetic manipulation work, the least stringent level being CI. The requirement for C3 is much more stringent than for C2.
Large-scale work
GMAC review, including certification of the facility and operational procedures, is required before large-scale work can commence. Large-scale work has four levels of physical containment, as follows (5) GILSP is the lowest level of containment. The requirement for C3-LS is much more stringent than for C2-LS.
Concerns regarding products derived from molecular biology
A wide range of proteins, peptides and other substances for use in biological products can now be produced by novel biotechnology processes. These products include the following: -naturally-occurring human and animal hormones (e.g. insulin, bovine somatotropin, porcine somatotropin) -blood products (e.g. tissue plasminogen) -cytokines (e.g. interferons, cytotoxin) -monoclonal and polyclonal antibodies -some viral and bacterial antigens used for new vaccine preparation.
Three major concerns associated with these products are the method of production, quality control (including purification procedures) and the possible presence of impurities.
For example, in the case of monoclonal antibodies of murine origin, the two most important considerations are the possible contamination of the antibodies with extraneous agent(s), and unintentional immunological cross-reactivity of the antibody with animal tissue antigens other than those targeted. The information evaluated therefore includes the following (2):
-source and characteristics of the parent myeloma cell-line -source of the immune parental cells, including information on the species and strain, and the immunisation procedure used in the preparation of the donor animal (where antibodies are raised against microorganisms, details of the microorganism are required, including its pathogenicity to humans and animals) -characteristics of the hybridoma cell-line, including specificity -immunological properties of the monoclonal antibodies.
Release of genetically-manipulated organisms into the environment
When an organism is grown within a contained facility, it is possible to destroy the organism in the unlikely event that it exhibits unwanted characteristics. Once an organism is released into the environment, however, this option may not be available. This is not a new or unique dilemma for society. These risks are weighed each time a new variety of plant, animal, insect or microorganism is imported into Australia, or when new strains of commercially-significant crops and animals are bred in the country.
The release assessment focuses on the genetics of the product and the environmental implications of the release. Information considered therefore includes the following (8):
-nature of the organism or agent to be released (i.e. species, host range and pathogenicity [if any] to humans, animals or microorganisms) -genetics of the product (see 'Risk management for products of molecular biology' above) -genetic structure and genetic stability of the novel organism -predicted effects of the manipulation on the behaviour of the organism in its natural habitat -details of the production of the GMO, including quality control measure and transportation arrangements -information on the nature, method and magnitude of the release, and the potential risk to the environment -survival, persistence and dissemination of the released novel organism -monitoring and contingency planning.
Communication with the public about release
GMAC publishes a brief description of proposals for the planned release of GMOs into the environment in the Commonwealth Government Notices Gazette. Copies are also sent to interested individuals and organisations registered with GMAC for this purpose, and to the municipal council in the area where the release is to occur. The public has thirty days to comment to GMAC on the proposed release. When GMAC has assessed a planned release proposal, the Committee issues a public information sheet describing the proposal in detail, including a summary of the GMAC assessment of the proposal and reasons for the decisions taken.
Risk monitoring
The monitoring of day-to-day work in institutions where GMOs are handled is undertaken by the local IBC, while the overall monitoring of activities involving genetic manipulation is overseen by GMAC (7,9).
RISK ANALYSIS OF VETERINARY IMMUNOBIOLOGICALS AND THERAPEUTICS
Immunobiologicals and therapeutic products are assessed for efficacy (potency), safety and quality (i.e. purity and sterility) prior to registration by the NRA. For imported products, consideration and approval by AQIS of the quarantine aspects of the product are required before the NRA will consider evaluating the registration application. Similarly, with products derived from recombinant technologies, evaluation of the registration application by the NRA cannot begin until GMAC approval has been obtained on the following safety aspects:
-safety of manufacture -safe use of the product in animals -operator safety -environmental safety.
Risk characterisation
Risk analysis of therapeutic biologicals follows the same analytical steps as detailed elsewhere in this paper. Characterisation of the safety hazards associated with the vaccine organism is established by evaluating various data, including the following (4) -procedures used to attenuate the parental strain -production methods, quality control (including potency, purity and sterility tests) and, in the case of killed vaccine, inactivation procedures.
Hazard identification
The hazards associated with biological therapeutic agents are determined by assessing information, including the following: 
Therapeutic agents
Risk assessment for therapeutic agents of biological origin is similar to that for vaccines, in that the assessment aims to ensure that products used to treat animals meet the NRA criteria for safety, potency, purity and sterility. For example, the information required for the evaluation of antitoxin includes the following:
-details of the source and identity of the antigen -information on the animals from which the blood was taken -identification of the immunoglobulins (i.e. demonstration that the antiserum specifically neutralises the toxin of concern, rendering the toxin harmless to susceptible animals) -purity (i.e. free from disease-causing organisms and foreign proteins) -details of safety, sterility and potency -production methods and quality controls.
Communication
Consistent with the NRA policy of an open and transparent registration process, and with the NRA goal of public involvement in the decision-making process, an opportunity is given for the public to express its views on new molecules before a decision on registration is made. A public notice is placed in the major daily newspapers in each State, informing the public of the application under consideration. A summary of the NRA findings -called a 'Public Release Summary' (PRS) -is assembled and is made available to the public on request. The public has thirty days to comment on the PRS.
Monitoring
Monitoring of the safety and efficacy of registered products is achieved through two distinct programmes: the Compliance and Surveillance Programme, and the NRA Adverse Experience Reporting Programme.
ISSUES FOR CONSIDERATION
Before governments can approve the free movement of veterinary biologicals, a system must be mutually agreed to determine the risks associated with the products under consideration.
Therefore, there is a need to develop international standards to facilitate safe importation and registration of vaccines and other biological products. Standards must include 'good manufacturing practice' and acceptable methods for determining quality, safety and efficacy. In addition, international policy on standards of acceptable risk and internationally-accepted risk assessment methodology must be developed.
A numerical scale must be established for quantitative risk assessment. Quantitative risk assessment is based on the premise that when we ask 'What are the risks involved in this action or project?', we are really asking three questions (C.G. Osborne, unpublished findings, 1992):
-What can go wrong?
-What is the probability that it will happen? -If it does happen, what will the consequences be?
While the screening risk assessments currently used by most countries, including Australia, have the advantage of being simple and inexpensive to complete, they lack the consensus-building qualities of quantitative risk assessment, and are of little use when the issues become less clear and the data more questionable. Thus, in instances where screening risk assessment fails to provide the necessary consensus, qualitative risk analysis can be used to develop a clear and complete picture of the potential risks (i.e. cost, benefit and risk) associated with an import candidate or GMO (C.G. Osborne, unpublished findings, 1992).
Risk assessment procedures used by the Codex Alimentarius Commission and its subsidiary advisory bodies have been under intense scrutiny, and some of the recommendations arising from these discussions are equally pertinent here (3): a) Development of decision-making criteria to service a predictable and consistent risk analysis process should focus, in the first instance, on elements of risk assessment within the scientific review process, rather than on elements of risk management.
b) Wherever possible, regulatory authorities should adopt specific decision-making criteria for each decision step. c) Subject committees should be established to develop uniform hazard identification and characterisation procedures, and to formulate a ranking for different groups of biologicals.
d) Minimum data requirements should be clearly described so that judgements on adequacy (acceptable/unacceptable) are consistent and predictable. e) Comparable standards and specifications employed by national agencies should be mutually recognised, and differences should be reduced where risk analysis shows that these differences are unjustified. f) Countries should provide information on their risk assessments to the expert groups, to assist the latter in identifying reasons for differences in the interpretation and assessment of data.
g) The many variables in socio-economic modelling dictate that the development of strict decision-making criteria and policy options for risk management of veterinary biologicals is not a practical proposition in the short term. In the absence of an international system for evaluating the perceived or known benefits and risks, reaching risk management decisions by consensus is the most practical solution.
CONCLUSIONS
The science of risk analysis, together with decision theory, technology for information management, and the more traditional subjects of epidemiology, statistics and economics, represent a powerful collection of tools. These tools have the potential to help analysts and decision-makers to collect information, judge risk, and make decisions in a manner which is transparent, consistent and documented. 
